Morphine Sulfate ER (Morphine Sulfate) Patent Expiration, LOE Window & CMS Spending

Morphine Sulfate ER (Morphine Sulfate) by Hikma Pharmaceuticals: FDA Orange Book LOE 2034-03-12, 3 AB generics, $66.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN022195 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-12
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$66.0M
2024 Medicare Part D Spend$58.2M
2024 Medicaid Spend$7.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.